Navigation Links
SeraCare Shareholders Approve Acquisition by Linden Capital Partners
Date:4/18/2012

MILFORD, Mass., April 18, 2012 /PRNewswire/ -- SeraCare Life Sciences, Inc. (NASDAQ: SRLS), a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, announced that, at a special meeting of shareholders held today, its shareholders voted to adopt the merger agreement with Project Plasma Holdings Corporation and Project Plasma Merger Corp., affiliates of Linden Capital Partners. Linden Capital Partners is a Chicago-based private equity firm that focuses on middle market leveraged buyout investments in the healthcare and life science industries.

(Logo:  http://photos.prnewswire.com/prnh/20110324/NE70714LOGO )

Under the terms of the merger agreement, holders of outstanding shares of common stock of SeraCare will receive $4.00 per share. The transaction is expected to close on Friday, April 20, 2012 after the close of business, subject to the satisfaction of customary closing conditions. In addition, shareholders also voted to approve certain compensation arrangements for SeraCare's named executive officers in connection with the merger.

About Linden Capital Partners:

Linden is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's investment strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden has advised SeraCare that it currently manages $575 million in capital. For additional information, please visit www.lindenllc.com.

About SeraCare Life Sciences, Inc.:

SeraCare serves the g
'/>"/>

SOURCE SeraCare Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SeraCare Life Sciences Secures $20 Million Credit Facilities
2. SeraCare Life Sciences to Report First Quarter 2011 Financial Results on February 11, 2011
3. SeraCare Reports First Quarter Fiscal Year 2011 Results
4. SeraCare Life Sciences Appoints Sean OConnor as Vice President of Sales and Marketing
5. SeraCare Announces the Election of Joseph Nemmers and Kevin Hrusovsky to the Board of Directors
6. SeraCare Reports Second Quarter Fiscal Year 2011 Financial Results
7. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
8. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
9. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
10. Mymetics Corporation Important Shareholders Information Conference Call
11. Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... “Science can be fun” was a key ... an “Introduce a Girl to Engineering Day” at the University ... science and technology were presented by the UT Austin SPIE ... total of $60,000 in International Year of Light ... and photonics . The IYL grants are in addition to ...
(Date:4/1/2015)... , April 1, 2015 Emerson Ecologics is ... The Business of Better Medicine . The conference will ... to develop a thriving and fulfilling practice. ... La Costa Resort and Spa, the conference will be ... expect to accomplish key projects and leave with an ...
(Date:4/1/2015)... 1, 2015 Goldman Small Cap Research, a ... and microcap sectors, announced today that it has issued ... PMCB), a publicly traded clinical stage biotechnology company focused ... To view the sponsored research article, along with disclosures ... please visit www.GoldmanResearch.com .  In ...
(Date:4/1/2015)... DUBLIN , Mar. 30, 2015 Research ... announced the addition of the "Blood Screening ... Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western ... Bank, Hospital) - Forecasts to 2019 " ... screening market is expected to reach $2.55 billion ...
Breaking Biology Technology:Fun, wonder, importance of light are messages in SPIE Student Chapter IYL2015 events 2Fun, wonder, importance of light are messages in SPIE Student Chapter IYL2015 events 3Emerson Ecologics Announces First Annual Conference for Integrative Healthcare Practitioners 2Emerson Ecologics Announces First Annual Conference for Integrative Healthcare Practitioners 3Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 2Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 3Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 4Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 2Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 3
... , ... --,China Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: CYXN; ,China ... of pharmaceuticals in Northeastern China, today announced it has,completed ... List. , The Chinese government ...
... , NOVATO, Calif., Nov. 30 BioMarin Pharmaceutical Inc. ... and Drug Administration (FDA) has granted orphan drug designation ... disease Lambert Eaton Myasthenic Syndrome (LEMS). 3,4-DAP has ... Also, in October 2009, the Committee for Medicinal Products ...
... , SEATTLE, ... MTA: CTIC) announced today that its new class of ... potency and activity compared to currently available platinum-based compounds ... cancer cell lines. The results were presented in ...
Cached Biology Technology:China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3
(Date:3/23/2015)... March 23, 2015  In the 2014 fiscal year, ... conviction losses. This figure accounts for a fraction of ... The Nilson Report, exceeds $11 billion globally. The polygraph ... a crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test ...
(Date:3/20/2015)... Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced the addition ... report to their offering. This report analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2013 ...
(Date:3/19/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet ... on Washington DC,s Fox 5 News ... Next Great Thing", host Laura Evans calls the ... really big breakthrough in mobile payment.,  Award-winning ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... is the liquid elixir that nurtures the growth of billions ... ample supply of water for farming and agriculture often means ... world, however, suffer from the opposite - the growing scarcity ... drought and desertification to climate change and climate variability, pollution, ...
... DC Scientists at the Lombardi Comprehensive Cancer Center at ... million grant to tease apart in the most comprehensive ... in breast cells in cancer development and treatment. This protein ... breast cancer and how she will fare during her treatment. ...
... 22nd, 2010-Riparian areas, ecosystems caught between the land ... temporal variability. Effectively managing and protecting riparian areas ... concepts. Fortunately, scientists are investigating new approaches in ... One of those approaches is photography. By taking ...
Cached Biology News:More water for life 2More water for life 3Lombardi receives $7.5 million grant for Breast Cancer Center for Cancer Systems Biology 2Lombardi receives $7.5 million grant for Breast Cancer Center for Cancer Systems Biology 3Learning about riparian areas from photographs 2
... microarray data using Asuragens bioinformatics expertise. We ... to extensive data analysis using the most ... in combination with the Gene Expression Profiling ... ,Normalization and basic statistical analysis including publication ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. Material: cap ...
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap, packed in double bag. (20/ca) Packaging: ...
... Mass Analyzer for superior sensitivity, mass accuracy, and resolving power., ... Precursor ion selection range: 150 - 4000 m/z, * Resolution: 14,000 ... reference, * Dynamic range: 4 orders of magnitude ... ...
Biology Products: